Consiglio Nazionale Delle Ricerche

Universita Cattolica Del Sacro Cuore

Molipharma S.r.l.

Molipharma R&d S.r.l.

Davide Pirolli

Maria Cristina De Rosa

Francesco Ria

Bruno Giardina

Gianfranco Ferraccioli

Chiara Nicolo′

Giovanni Scambia

Marco Petrillo

Marta De Donato

Daniela Gallo

Benedetta Righino

Chiara Nicolo'

The mitotic kinases regulating the dynamics of centrosomes and the functions of the mitotic spindle are potential targets for the antitumour therapy. In the present invention some molecules with inhibitory activity on NEK6 have been identified. The present invention relates to such molecules and to the compositions including them for use as inhibitors of NEK6 in a method of treatment of tumours both in monotherapy and in combinations with other drugs.

NEK6 kinase inhibitors useful for the treatment of solid tumors

The T cells specific to human collagen type II, one of the possible autoantigens, have a crucial role in the development of rheumatoid arthritis in the context of HLA-DR4. The protein-protein interactions between the T cell receptor (TCR) and the type II collagen linked to the allele MHC of class II HLA-DR4 may thus represent the target for the development of new drugs against rheumatoid arthritis. Using computational virtual screening techniques, families of pharmacologically active molecules have been identified that interfere with the TCR/collagen II-MHCII interaction. The compounds identified here open up new possibilities in the treatment of rheumatoid arthritis.

TCR/MHCII-collagen interaction inhibitors useful for the treatment of rheumatoid arthritis

The T cells specific to human collagen type II, one of the possible autoantigens, have a crucial role in the development of rheumatoid arthritis in the context of HLA-DR4. The protein-protein interactions between the T cell receptor (TCR) and the type II collagen linked to the allele MHC of class II HLA-DR4 may thus represent the target for the development of new drugs against rheumatoid arthritis. Using computational virtual screening techniques, families of pharmacologically active molecules have been identified that interfere with the TCR/collagen ll-MHCII interaction. The compounds identified here open up new possibilities in the treatment of rheumatoid arthritis.

TCR/MHCII-collagen interaction inhibitors useful for treatment of rheumatoid arthritis

Growing community of inventors

Rome, Italy

Davide Pirolli